Concise review: Making and using clinically compliant pluripotent stem cell lines

Stem Cells Translational Medicine

Volumn 4, Issue 4, 2015, Pages 381-388

  Carpenter, Melissa K ^a   Rao, Mahendra S ^b,c  

^a Carpenter Group Consulting Inc   (United States)

^b NxCell Inc   (United States)

^c Q Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL CULTURE; CELL MATURATION; CELL NUCLEUS TRANSPLANTATION; COST; EMBRYONIC STEM CELL; GENETIC ENGINEERING; GOOD MANUFACTURING PRACTICE; HUMAN; HYBRID CELL; NATIONAL HEALTH ORGANIZATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHENOTYPE; PLURIPOTENT STEM CELL LINE; STEM CELL TRANSPLANTATION; TIME; TISSUES; BIOLOGICAL THERAPY; CELL DIFFERENTIATION; CYTOLOGY; GENETICS; PLURIPOTENT STEM CELL; UNITED STATES;

CELL DIFFERENTIATION; CELL- AND TISSUE-BASED THERAPY; EMBRYONIC STEM CELLS; HUMANS; PLURIPOTENT STEM CELLS; STEM CELL TRANSPLANTATION; UNITED STATES;

EID: 84929940526     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2014-0202     Document Type: Article

References (46)

1. Thomson JA, Itskovitz-Eldor J, Shapiro SS et al. Embryonic stem cell lines derived from human blastocysts. Science 1998;282:1145–1147.
2. NIH. Grants & funding: NIH Human Embryonic Stem Cell Registry. Available at: http://grants.nih.gov/stem_cells/registry/current.htm. Accessed September 15, 2014.
3. Rao M., Scalablehuman ES culture for therapeutic use: Propagation, differentiation, genetic modification and regulatory issues. Gene Ther 2008;15:82–88.
4. Rao M, Condic ML. Alternative sources of pluripotent stem cells: Scientific solutions to an ethical dilemma. Stem Cells Dev 2008;17:1–10.
5. Carpenter MK, Frey-Vasconcells J, Rao MS. Developing safe therapies from human pluripotent stemcells. NatBiotechnol 2009;27:606–613.
6. Bradley JA, Bolton EM, Pedersen RA. Stem cell medicine encounters the immune system. Nat Rev Immunol 2002;2:859–871.
7. Turner M, Leslie S, Martin NG et al. Toward the development of a global induced pluripotent stem cell library. Cell Stem Cell 2013;13: 382–384.
8. Zimmermann A, Preynat-Seauve O, Tiercy JM et al. Haplotype-based banking of human pluripotent stem cells for transplantation: Potential and limitations. Stem Cells Dev 2012;21:2364–2373.
9. Gurdon JB, Wilmut I. Nuclear transfer to eggs and oocytes. Cold Spring Harb Perspect Biol 2011;3:3.
10. Tian XC, Kubota C, Enright B et al. Cloning animalsbysomaticcellnucleartransfer—Biological factors. Reprod Biol Endocrinol 2003;1:98.
11. Noggle S, Fung HL, Gore A et al. Human oocytes reprogram somatic cells to a pluripotent state. Nature 2011;478:70–75.
12. Tachibana M, Amato P, Sparman M et al. Human embryonic stemcells derived by somatic cell nuclear transfer. Cell 2013;153:1228–1238.
13. Malik N, Rao MS. A review of the methods for human iPSC derivation. Methods Mol Biol 2013;997:23–33.
14. Takahashi K, Okita K, Nakagawa M et al. Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc 2007;2:3081–3089.
15. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663–676.
16. Yamanaka S. Induced pluripotent stem cells: Past, present, and future. Cell Stem Cell 2012;10:678–684.
17. Zhao T, Zhang ZN, Rong Z et al. Immunogenicity of induced pluripotent stem cells. Nature 2011;474:212–215.
18. Araki R, Uda M, Hoki Y et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 2013;494:100–104.
19. Kamao H, Mandai M, Okamoto S et al. Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application. Stem Cell Reports 2014;2:205–218.
20. Morizane A, Doi D, Kikuchi T et al. Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate. Stem Cell Reports 2013;1:283–292.
21. Capecchi MR. Altering thegenomeby homologous recombination. Science 1989;244: 1288–1292.
22. Thomas KR, Capecchi MR. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell 1987;51:503–512.
23. Li M, Suzuki K, Kim NY et al. A cut above the rest: Targeted genome editing technologies in human pluripotent stem cells. J Biol Chem 2014;289:4594–4599.
24. Xue H, Wu J, Li S et al. Genetic modification in human pluripotent stem cells by homologous recombination and CRISPR/Cas9 system. Methods Mol Biol 2014 [Epub ahead of print].
25. Peters DT, Cowan CA, Musunuru K. Genome Editing in Human Pluripotent Stem Cells. StemBook. Cambridge, MA: Harvard Stem Cell Institute, 2013.
26. Caulfield T, McGuire A. Athletes’ use of unproven stem cell therapies: Adding to inappropriate media hype? Mol Ther 2012;20: 1656–1658.
27. Georgieva BP, Love JM. Human induced pluripotent stem cells: A review of the US patent landscape. Regen Med 2010;5:581–591.
28. Ikegaya H. Bioethics: Tighten up Japan’s stem-cell practices. Nature 2012;489:33.
29. Magnus D. Translating stem cell research: Challenges at the research frontier. J Law Med Ethics 2010;38:267–276.
30. Sipp D, Turner L. Stem cells. U.S. regulation of stem cells as medical products. Science 2012;338:1296–1297.
31. Vrtovec KT, Scott CT. Patenting pluripotence: The next battle for stem cell intellectual property. Nat Biotechnol 2008;26:393–395.
32. Andrews PW, Cavanagro J, Deans R et al. Harmonizing standards for producing clinicalgrade therapies from pluripotent stem cells. Nat Biotechnol 2014;32:724–726.
33. Naldini L. Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet 2011;12:301–315.
34. Frey-Vasconcells J, Whittlesey KJ, Baum E et al. Translation of stem cell research: Points to consider in designing preclinical animal studies. STEMCELLS TRANSLATIONALMEDICINE 2012;1:353–358.
35. Kleitman N, Rao MS, Owens DF. Pluripotent stem cells in translation: A Food and Drug Administration-National Institutes of Health collaboration. STEM CELLS TRANSLATIONAL MEDICINE 2013;2:483–487.
36. Panchision DM. Meeting report: Using stem cells for biological and therapeutics discovery in mental illness, April 2012. STEM CELLS TRANSLATIONAL MEDICINE 2013;2:217–222.
37. Jonlin EC. Differing standards for the NIH Stem Cell Registry and FDA approval render most federally funded hESC lines unsuitable for clinical use. Cell Stem Cell 2014;14:139–140.
38. U.S. Food and Drug Administration. Available at: http://www.fda.gov/regulatoryinformation/guidances/ucm122049.htm.Accessed September 15, 2014.
39. Lomax GP, Hull SC, Lowenthal J et al. The DISCUSS Project: Induced pluripotent stem cell lines from previously collected research biospecimens and informed consent: Points to consider. STEM CELLS TRANSLATIONAL MEDICINE 2013; 2:727–730.
40. Lowenthal J, Lipnick S, RaoMet al. Specimen collection for induced pluripotent stem cell research: Harmonizing the approach to informed consent. STEM CELLS TRANSLATIONAL MEDICINE 2012;1:409–421.
41. Assawachananont J, Mandai M, Okamoto S et al. Transplantation of embryonic and induced pluripotent stem cell-derived 3D retinal sheets into retinal degenerative mice. Stem Cell Reports 2014;2:662–674.
42. Kanemura H, Go MJ, Shikamura M et al. Tumorigenicity studies of induced pluripotent stem cell (iPSC)-derived retinal pigment epithelium (RPE) for the treatment of age-related macular degeneration. PLoS One 2014;9:e85336.
43. Bock C, Kiskinis E, Verstappen G et al. Reference maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell 2011;144: 439–452.
44. Müller FJ, Schuldt BM, Williams R et al. A bioinformatic assay for pluripotency in human cells. Nat Methods 2011;8:315–317.
45. Rouhani F, Kumasaka N, de BritoMCet al. Genetic background drives transcriptional variation in human induced pluripotent stem cells. PLoS Genet 2014;10:e1004432.
46. Pharmaceuticals and Medical Devices Agency (PMDA). Japan’s gatekeeper of medical products. Available at: http://www.pmda.go.jp/english/about/pdf/nature_20140501_e.pdf. Accessed September 15, 2014.